The National Puerto Rican Chamber of Commerce firmly opposes international reference pricing for pharmaceuticals. Our opposition is rooted in two key concerns: First, this approach can significantly delay patient access to new and innovative medicines. Second, it threatens to stifle the pharmaceutical industry's research and development, potentially leading to a decrease in the discovery of groundbreaking new treatments, while further impeding an industry vital to Puerto Rico's economy. These factors highlight the inherent risks of adopting a pricing strategy that might ultimately hinder both patient care and pharmaceutical innovation.